Gαs Protein Expression Is an Independent Predictor of Recurrence in Prostate Cancer

Table 2

Characterization of the cohort of 347 prostate cancer samples.

Variable	Number	Gαs positive	Gαs negative	𝜒^2	𝑃
All patients	347	160	187
Age at diagnosis (years)
≤73	211	96	115	0.081	0.826
>74	136	64	72
Clinical stage at diagnosis
I	49	31	18	9.358	<0.001*
II	125	61	64
III	117	51	66
IV	56	17	39
Gleason score at diagnosis
2–6	145	83	62	15.692	<0.001*
7	127	54	73
8–10	75	23	52
Preoperative PSA (ng/mL)
<35	184	99	85	9.334	0.003*
≥35	163	61	102
Angiolymphatic invasion
Presence	114	48	66	1.096	0.350
Absence	233	112	121
Extraprostatic extension
Presence	105	53	52	0.993	0.351
Absence	242	135	107
Positive surgical margin
Presence	128	60	68	0.048	0.911
Absence	219	100	119
Seminal vesicle invasion
Presence	172	78	94	0.079	0.830
Absence	175	82	93
Positive lymph node
Presence	34	14	20	0.369	0.590
Absence	313	146	167
PSA progression
Presence	213	89	124	4.153	0.047*
Absence	134	71	63

∗Significant differences of Gαs expression among different clinical factors groups in prostate cancer samples.